青少年症状性COVID-19住院与疾病进展相关合并症分析
该多中心回顾性队列研究纳入1877例12-17岁症状性COVID-19青少年,分析合并症与28天内住院的关系。调整种族/民族后,镰状细胞病、免疫抑制状态、肥胖、糖尿病、神经系统疾病和肺病(除外轻度哮喘)与住院风险升高独立相关,心脏病和慢性肾病无独立关联。建议对具有这些合并症的青少年优先考虑治疗以避免住院。
要点
- 镰状细胞病和免疫抑制状态与住院风险升高关联最强。
- 肥胖、糖尿病、神经系统疾病和肺病亦独立增加住院风险。
- 心脏病和慢性肾病未显示与住院独立相关。
核心结论
- 镰状细胞病、免疫抑制状态、肥胖、糖尿病、神经系统疾病和肺病(除外轻度哮喘)与症状性COVID-19青少年住院独立相关。
- 具有上述合并症的急性COVID-19青少年应优先考虑治疗以避免住院。
研究设计与样本
- 多中心回顾性队列研究,数据来自美国儿科COVID-19注册登记。
- 纳入1877例12-17岁症状性COVID-19患者,分析合并症与诊断后28天内住院的关系。
- 采用多变量logistic回归模型,调整种族/民族因素。
主要发现
- 284例(15%)在COVID-19诊断后28天内住院。
- 调整种族/民族后,镰状细胞病与住院风险升高独立相关(aOR 6.9;95% CI 3.0-15.9)。
- 免疫抑制状态与住院风险升高独立相关(aOR 6.4;95% CI 3.8-10.8)。
- 肥胖与住院风险升高独立相关(aOR 3.2;95% CI 2.1-4.9)。
- 糖尿病(aOR 3.0;95% CI 1.4-6.2)、神经系统疾病(aOR 2.8;95% CI 1.8-4.3)和肺病(除外轻度哮喘)(aOR 1.9;95% CI 1.2-3.1)与住院风险升高独立相关。
关键数值与推荐
- 评估的合并症包括肥胖、慢性肾病、糖尿病、免疫抑制疾病或治疗、镰状细胞病、心脏病、神经系统疾病/神经发育障碍和肺病(除外轻度哮喘)。
- 心脏病和慢性肾病在调整模型中未显示与住院独立相关。
临床怎么用
- 对具有镰状细胞病、免疫抑制状态、肥胖、糖尿病、神经系统疾病或肺病(除外轻度哮喘)的12-17岁症状性COVID-19患者,应优先考虑单克隆抗体或抗病毒治疗以降低住院风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify subgroups likely to benefit from monoclonal antibody and antiviral therapy by evaluating the relationship between comorbidities and hospitalization among US adolescents with symptomatic coronavirus disease 2019 (COVID-19). STUDY DESIGN: We analyzed the relationship between presence of comorbidities and need for hospitalization within 28 days of COVID-19 diagnosis for adolescents aged 12-17 years listed in the Pediatric COVID-19 US registry, a multicenter retrospective cohort of US pediatric patients with COVID-19. Comorbidities assessed included obesity, chronic kidney disease (CKD), diabetes, immunosuppressive disease or treatment, sickle cell disease (SCD), heart disease, neurologic disease/neurodevelopmental disorders, and pulmonary disease (excluding patients with mild asthma). We used multivariable logistic regression to determine race/ethnicity-adjusted associations between comorbidities and hospitalization. RESULTS: A total of 1877 patients met our inclusion criteria, of whom 284 (15%) were hospitalized within 28 days of their COVID-19 diagnosis. In a race/ethnicity-adjusted model, the following comorbidities were independently associated with increased odds of hospitalization: SCD (aOR, 6.9; 95% CI, 3.0-15.9), immunocompromising condition (aOR, 6.4; 95% CI, 3.8-10.8), obesity (aOR, 3.2; 95% CI, 2.1-4.9), diabetes (aOR, 3.0; 95% CI, 1.4-6.2), neurologic disease (aOR, 2.8; 95% CI, 1.8-4.3), and pulmonary disease (excluding mild asthma) (aOR, 1.9; 95% CI, 1.2-3.1). Heart disease and CKD were not independently associated with hospitalization. CONCLUSIONS: SCD, immunocompromising conditions, obesity, diabetes, neurologic disease, and pulmonary disease (excluding mild asthma) were associated with hospitalization for symptomatic COVID-19. Adolescents with acute COVID-19 and these comorbidities should be prioritized for consideration of therapy to avert hospitalization.
引用
- Campbell JI, Dubois MM, Savage TJ, et al. Comorbidities Associated with Hospitalization and Progression Among Adolescents with Symptomatic Coronavirus Disease 2019. J Pediatr. 2022. PMID: 35240138. doi:10.1016/j.jpeds.2022.02.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。